On January 2, 2025, Eli Lilly China announced that Mounjaro (tirzepatide injection) officially entered the Chinese market and covered two indications.Two indications:
Adults with type 2 diabetes (T2DM) who have poor blood glucose control despite diet control and exercise, and who are receiving metformin and/or sulfonylurea drugs;
Adults with initial BMI meeting the following requirements for long-term weight management: ≥28kg/m(overweight), or ≥24kg/m(obesity) and with at least one weight-related comorbidity (e.g., hypertension, abnormal lipid metabolism, hyperglycemia, obstructive sleep apnea, cardiovascular disease, etc.).
The above indications were approved by the National Medical Products Administration in May and July 2024, respectively.
There are about 148 million adult diabetes patients in China. Currently, nearly half of Chinese diabetes patients do not meet the blood glucose control target (HbA1c≥7.0%). Mounjaro can directly and indirectly act on multiple organs and tissues that cause pathological and physiological defects of T2DM, and can achieve stronger efficacy in core pathological tissues such as pancreatic β cells.
The four specifications of Mounjaro currently on the Chinese market are: 2.5mg:0.5ml, 5mg:0.5ml, 7.5mg:0.5ml, 10mg:0.5ml.